On June 25, MSD China WeChat official account announced that its PD-1 inhibitor Pabolizumab (trade name: Kereida®) had been approved by the National Drug Administration (NMPA) of China to combine ...

On June 25th, Merck announced that its PD-1 inhibitor, Pembrolizumab (trade name: Koreda®), has been approved by the National Medical Products Administration (NMPA) of China for first-line treatm ...